Eddy Edson
Well-Known Member
- Relationship to Diabetes
- Type 2
CV risk continues to reduce, at the same rate, the lower you go, with no increase in drug-related adverse effects. Similar picture for non-HDL-C and apolipoprotein B reduction.
Over the last 2 decades, we have seen the guidelines shift to lower and lower LDL-C goals on the basis of clinical trials demonstrating that lower is better. The European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines have selected an LDL-C goal of <40 mg/dL as the next step in this progression. Previous clinical trials have proven that such levels are safe,3 and we have demonstrated in this study that there is continued effectiveness even below 40 mg/dL in patients with high-risk ASCVD.
In conclusion, these data support the European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines recommendations and suggest that lowering LDL-C well below 40 mg/dL in a wider range of patients with ASCVD would further lower cardiovascular risk.
